GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported a share buyback transaction executed via BNP Paribas SA on 21 October 2025, purchasing 250,000 ordinary shares at prices between 1,635.00p and 1,650.00p, with a volume-weighted average price of 1,642.48p. The shares will be held as Treasury shares and the purchase forms part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,113,500 ordinary shares. Following this transaction, GSK holds 252,578,344 shares in treasury and has 4,062,838,575 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed that treasury-held ordinary shares represent 6.22% of voting rights.
GSK plc filed a Form 6-K announcing headline results from the INFRONT-3 trial of latozinemab in frontotemporal dementia due to progranulin mutation (FTD-GRN). The drug achieved a statistically significant effect on the biomarker co-primary endpoint, increasing plasma progranulin (PGRN), but did not show benefit on the clinical co-primary endpoint of slowing FTD-GRN progression. Secondary and exploratory endpoints also did not show treatment-related effects. Preliminary safety data have not highlighted major concerns, and deeper analyses are ongoing.
Based on these results, GSK will discontinue the open-label extension portion of INFRONT-3 and the continuation study for latozinemab. Full results will be presented at an upcoming medical congress. GSK and Alector have collaborated on progranulin-elevating antibodies since July 2021, sharing development responsibilities and costs after Phase 2 proof-of-concept.
GSK reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine). After approval by the European Commission, expected in December 2025, the ready-to-use format would eliminate reconstitution of two separate vials, simplifying administration for healthcare professionals.
Shingrix has been approved in the EU since 2018 for adults 50+ and since 2020 for adults 18+ at increased risk of herpes zoster. The positive opinion is based on data confirming technical comparability between the prefilled syringe and the current presentation. Shingles affects approximately 1.7 million people in Europe each year.
GSK plc repurchased 220,000 ordinary shares on 20 October 2025 as part of its existing buyback programme, executed via BNP Paribas SA. The shares will be held as treasury shares.
On the day, prices ranged from 1,615.00p to 1,637.00p, with a volume‑weighted average price of 1,628.13p. Since 30 September 2025, GSK has purchased 4,863,500 ordinary shares under this programme.
After this transaction, GSK holds 252,328,344 shares in treasury and has 4,063,088,575 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,088,575, and the percentage of voting rights attributable to treasury shares is 6.21%.
GSK plc reported positive pivotal Phase 3 PIVOT-PO results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTIs), including pyelonephritis. The trial was stopped early for efficacy and met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin based on overall response at the test-of-cure visit.
Oral tebipenem HBr (600 mg) achieved a 58.5% overall success rate (261/446) versus 60.2% for IV imipenem-cilastatin (500 mg; 291/483), with an adjusted treatment difference of −1.3% (95% CI: −7.5%, 4.8%). Clinical cure rates were 93.5% vs 95.2%, and microbiological responses were 60.3% vs 61.3%, respectively. The safety profile was generally similar to imipenem-cilastatin, with diarrhea and headache the most frequent, mild-to-moderate events.
GSK plans to work with US regulators to include these data in a filing in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem in the US for cUTIs, potentially providing a home-based treatment alternative.
GSK plc reported a routine share repurchase under its existing buyback programme. On 17 October 2025, the company bought 414,000 ordinary shares at prices between 1,597.50p and 1,620.50p, with a volume‑weighted average price of 1,608.93p. The shares will be held as treasury shares and the trades were executed by BNP Paribas SA.
Since 30 September 2025, GSK has purchased 4,643,500 ordinary shares. After this transaction, GSK holds 252,108,344 shares in treasury and has 4,063,308,575 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,063,308,575, and the percentage of voting rights attributable to treasury shares is 6.20%.
GSK plc reported a routine share buyback. Acting through BNP Paribas SA, the company purchased 310,000 ordinary shares on 16 October 2025 at prices between 1,621.50p and 1,637.00p per share, with a volume-weighted average price of 1,629.84p. The shares will be held as Treasury shares under the existing non-discretionary buyback agreement announced on 30 September 2025. Since that date, GSK has purchased 4,229,500 shares.
Following this transaction, GSK holds 251,694,344 shares in treasury and has 4,063,719,485 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,719,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc reported insider acquisitions of American Depositary Shares through automatic dividend reinvestment. On October 14, 2025, ADSs were acquired at $43.9461 per ADS on the New York Stock Exchange, reflecting the reinvestment of dividends paid on October 9, 2025.
Hal Barron acquired 3,186.736 ADSs. James Ford acquired 321.543 ADSs. Shobie Ramakrishnan acquired 387.334 ADSs. Each entry is recorded as a single transaction, with the instrument identified as GSK ADSs (ISIN: US37733W2044).
These transactions are routine dividend reinvestments by directors and senior management and do not reflect an open‑market discretionary purchase program.
GSK plc repurchased 405,500 ordinary shares on 15 October 2025 as part of its existing buyback programme, executed by BNP Paribas SA under a non-discretionary agreement announced on 30 September 2025. The shares were bought at a volume-weighted average price of 1,617.97p, within a price range of 1,608.00p to 1,633.00p, and will be held as treasury shares.
Since 30 September 2025, the company has purchased 3,919,500 ordinary shares. Following this transaction, GSK holds 251,384,344 ordinary shares in treasury and has 4,064,029,485 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,064,029,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc reported routine insider transactions on a Form 6‑K, disclosing that senior executives increased their interests through dividend reinvestment on 2025-10-10. The reinvestments followed dividends paid on 9 October 2025 and were executed in company plans on the London Stock Exchange and, for ADSs, the New York Stock Exchange.
Most entries reflect an increase in notional interest within the Deferred Annual Bonus Plan at £16.4000 per Ordinary Share, including the CEO 3,924 shares, the CFO 1,264 shares, and other executives such as Luke Miels 1,670 shares and Regis Simard 1,134 shares. One ADS transaction shows 417 ADSs at $43.4400 for Shobie Ramakrishnan on the NYSE.
Separately, the CEO acquired 8,786.741 Ordinary Shares at £16.4000 under the Performance Share Plan, which is subject to a 2‑year holding period. Additional small ISA purchases include David Redfern 20 shares at £16.3499 and the Company Secretary 17 shares at £16.3499.